Heindel_Reading

Heindel_Reading - POINT OF CARE TESTING By Ned D. Heindel...

Info iconThis preview shows pages 1–3. Sign up to view the full content.

View Full Document Right Arrow Icon
POINT OF CARE TESTING By Ned D. Heindel Professor of Chemistry ndh0@lehigh.edu [do this before class] 1) Point-of-Care Testing: An Introduction (2007) Sheryl L Gutierres, PharmD, U niversity of Oklahoma Timothy E Welty, PharmD, Samford University DATA SYNTHESIS: Point-of-care testing devices and technology are increasingly used in the delivery of care and therapeutic decision making. No studies have evaluated the impact of point-of-care testing, by itself, on patient care and outcomes. All studies have incorporated point-of-care testing with changes in the way patient care is delivered and have shown significant improvements when this approach is taken. The cost of point-of-care testing on a per test basis is sometimes greater than traditional laboratory testing, but that increased cost may be offset by improvements in the management of patient care, improvements in patient outcomes, and decreased utilization of the healthcare system. Point-of-care testing has been used successfully by pharmacists in disease management programs. Various government regulations and legislation impact the use of point-of-care testing . 2) On HIV testing -- read this http://www.cdc.gov/MMWR/preview/mmwrhtml/mm5236a4.htm
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
3) Abbott’s i-STAT BNP Cartridge Receives 510(k) Clearance (2006) Abbott Diagnostics has received 510(k) clearance from the FDA to market its i- STAT BNP cartridge. Four other cartridges obtained earlier FDA approval. BNP is a protein secreted by heart muscle when a patient has congestive heart failure (CHF). Determining the level of BNP in a patient's blood, an objective marker of the presence of heart failure, can help physicians quickly and more accurately diagnose and assess disease severity. Additionally, BNP testing at the patient bedside accelerates triage, diagnosis, treatment and disposition of patients, clearing overcrowded emergency departments, and patient survival rates . Nearly 80 percent of heart failure patients admitted to the hospital come through the emergency department. ..These patients present with shortness of breath, which doctors must assess to differentiate between heart attack, pulmonary embolism, asthma, the flu or a number of other conditions in addition to CHF. Point-of-care-testing (POCT) has labored under a number of burdens since its introduction, one of which has been the need to justify the additional unit cost of a test when compared to the cost of a comparable test performed in the central labs. The cost of centralized lab testing will usually be less expensive than the former because of economies of scale. Lab professionals tend to have a vested interest in performing test in the central lab in order to justify the cost of their high-throughput automated instruments and because, at least in the past, they have had more confidence in central lab quality control procedures. For those hospitals with pneumatic tube systems that permit rapid transit of specimens to the central lab, it is not uncommon for
Background image of page 2
Image of page 3
This is the end of the preview. Sign up to access the rest of the document.

Page1 / 16

Heindel_Reading - POINT OF CARE TESTING By Ned D. Heindel...

This preview shows document pages 1 - 3. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online